0.000USD0.000前場取引 08/04, 09:30 (ET)
格付け機関評価
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
指標
本指標機能は、各種テクニカル指標を用いて金融商品の数値分析と方向性評価を提供し、技術的な要約を表示します。
本機能ではMACD・RSI・KDJ・StochRSI・ATR・CCI・WR・TRIX・MAの9種類の主要テクニカル指標を網羅しています。時間軸はご自身のニーズに合わせて調整可能です。
テクニカル分析は投資判断の一要素に過ぎず、数値による方向性評価に絶対的な基準はありません。表示結果はあくまで参考情報であり、指標計算・要約の正確性について当方は責任を負いかねます。
財務指標
EPS

データなし
総売上高

データなし
企業名
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
企業コードOGN
企業名Organon & Co
最高経営責任者「CEO」Mr. Kevin Ali
ウェブサイトhttps://www.organon.com/